U.S. ‘No Fly List’ Leaks After Being Left in an Unsecured Airline Server

Novo Nordisk Extends Slide After Announcing Price-Cuts For Blockbuster Obesity Drugs Novo Nordisk shares in Copenhagen can't catch a bid. The liquidation is accelerating again after a Bloomberg headline on Tuesday morning: the Danish drugmaker will slash U.S. list prices for Wegovy and Ozempic next year. The move suggests that the new CEO is pursuing market share amid intensifying competition in the GLP-1 space. Jamey Millar, Novo's head of U.S. operations, was quoted by Bloomberg as saying the company set a monthly price of $675 for its family of semaglutide drugs,...

Adding to the growing list of ultimatums imposed on the Kurdish SDF, the Syrian Interior Ministry has announced they are giving SDF members until the end of February to disarm fully and completely return to civilian life. The new documents released by the Interior Ministry warn that the SDF members only have until month’s end […]